导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.57% | 1854/4773 |
| 近一周 | 0.19% | 123/5462 |
| 近一月 | 2.68% | 239/5421 |
| 近一季 | 3.11% | 388/5209 |
| 近半年 | -3.44% | 2212/4920 |
| 近一年 | 0.63% | 2518/4366 |
| 近两年 | 17.50% | 2698/2954 |
| 近三年 | 21.52% | 1416/2253 |
| 成立以来 | 62.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.94% 827/4961 |
-10.87% 4190/5312 |
- - |
- - |
| 2025 | -1.95% 3334/4813 |
-2.57% 2913/3635 |
3.04% 1190/4076 |
-3.95% 4015/4524 |
1.69% 1265/4813 |
| 2024 | 25.48% 260/3463 |
8.77% 171/2808 |
4.26% 222/3014 |
9.72% 2674/3129 |
0.84% 1160/3463 |
| 2023 | 13.20% 51/2656 |
7.14% 600/2280 |
5.49% 64/2385 |
3.15% 196/2515 |
-2.90% 554/2655 |
| 2022 | -2.05% 53/2207 |
0.13% 114/1919 |
-1.04% 1669/2016 |
-5.28% 71/2113 |
4.36% 556/2208 |
| 2021 | 8.99% 463/1822 |
6.90% 87/1255 |
-2.86% 1229/1330 |
4.81% 318/1466 |
0.13% 1167/1822 |
| 2020 | 2.63% 917/1250 |
-10.07% 745/1028 |
0.87% 996/1067 |
9.83% 614/1164 |
3.02% 947/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实沪深300红利低波动ETF联接A VS. 长安沪深300非周期A(740101) |